PL387312A1 - Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi - Google Patents

Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi

Info

Publication number
PL387312A1
PL387312A1 PL387312A PL38731209A PL387312A1 PL 387312 A1 PL387312 A1 PL 387312A1 PL 387312 A PL387312 A PL 387312A PL 38731209 A PL38731209 A PL 38731209A PL 387312 A1 PL387312 A1 PL 387312A1
Authority
PL
Poland
Prior art keywords
aplication
sulindac
metabolite
human colonic
supportive treatment
Prior art date
Application number
PL387312A
Other languages
English (en)
Inventor
Jacek Spławiński
Sylwia Flis
Original Assignee
Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością filed Critical Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL387312A priority Critical patent/PL387312A1/pl
Priority to PCT/PL2010/000015 priority patent/WO2010095965A1/en
Publication of PL387312A1 publication Critical patent/PL387312A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL387312A 2009-02-19 2009-02-19 Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi PL387312A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL387312A PL387312A1 (pl) 2009-02-19 2009-02-19 Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
PCT/PL2010/000015 WO2010095965A1 (en) 2009-02-19 2010-02-18 The use of sulindac and/or its metabolite as adjuvant treatment for colon cancer in humans

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL387312A PL387312A1 (pl) 2009-02-19 2009-02-19 Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi

Publications (1)

Publication Number Publication Date
PL387312A1 true PL387312A1 (pl) 2010-08-30

Family

ID=42122923

Family Applications (1)

Application Number Title Priority Date Filing Date
PL387312A PL387312A1 (pl) 2009-02-19 2009-02-19 Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi

Country Status (2)

Country Link
PL (1) PL387312A1 (pl)
WO (1) WO2010095965A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2478407C1 (ru) * 2011-09-05 2013-04-10 Федеральное государственное бюджетное учреждение Министерства здравоохранения и социального развития Российской Федерации "Медицинский радиологический научный центр" (ФГБУ МРНЦ Минздравсоцразвития России) Способ комбинированного лечения местно-распространенного рака желудка
AU2017357873B2 (en) * 2016-11-11 2022-02-24 Cellix Bio Private Limited Compositions and methods for the treatment of gastrointestinal polyps
RU2725079C2 (ru) * 2020-02-25 2020-06-29 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения местно-распространенного рака желудка
RU2765845C1 (ru) * 2021-02-24 2022-02-03 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ комбинированного лечения местнораспространённого кардиоэзофагельного рака

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002474A3 (cs) * 1999-08-12 2003-02-12 American Cyanamid Company Prostředek pro léčení nebo inhibici polypů tlustého střeva a kolorektální rakoviny obsahující NSAID a inhibitor EGFR kinasy
AU1767001A (en) * 1999-11-15 2001-05-30 Advanced Research And Technology Institute, Inc. Use of nsaids for the treatment of pancreatic cancer
EP1428528A1 (en) 2002-09-27 2004-06-16 Tiense Suikerraffinaderij N.V. Synergistic combinations of dietary fiber and NSAIDs for the treatment of cancer
JP2005247807A (ja) * 2004-03-08 2005-09-15 Japan Science & Technology Agency Ｎｓａｉｄを利用した癌治療用組成物
US8765808B2 (en) 2005-03-23 2014-07-01 Chs Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
ITMI20051107A1 (it) 2005-06-14 2005-09-13 Ctg Pharma S R L Metodo per il trattamento del cancro

Also Published As

Publication number Publication date
WO2010095965A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
HK1258817A1 (zh) 合成三萜類化合物及用以治病之方法
IL236831A0 (en) Expression of micro rna in peripheral narrow blood vessels in the human body, and their uses
IL223241A0 (en) Cysteamine derivatives and their use in the treatment of nash
HK1170485A1 (zh) -噻唑烷- -酮衍生物及其在癌症治療中的用途
GB0922085D0 (en) Cancer diagnosis and treatment
IL220661A0 (en) Beta-carbolines for use in the treatment of hearing loss and vertigo
HK1203482A1 (en) Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states pde4
EP2651894A4 (en) THIOSEMICARBAZONE COMPOUNDS FOR CANCER TREATMENT
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
PL387312A1 (pl) Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
IL209220A0 (en) Plant extract and its therapeutic use
GB0901837D0 (en) Cancer diagnosis and treatment
GB0905970D0 (en) Depsipeptides and their therapeutic use
GB0907098D0 (en) Cancer treatment and diagnosis
GB0920267D0 (en) Drug combination and its use in therapy
GB0820562D0 (en) Novel use and treatment
ZA201204014B (en) Use of secreted phospholipases a2 in the diagnosis and treatment of malaria
GB0722338D0 (en) Novel use and treatment
GB0809324D0 (en) Depsipeptides and their therapeutic use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)